BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

Jae In Park; Jae Hyun Jang; Geun Soo Park; Yunro Chung; Hye Jin You; Jae Hong Kim

doi:10.5483/BMBREP.2018.51.8.127

BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

Jae In Park
, Jae Hyun Jang
, Geun Soo Park
, Yunro Chung
, Hye Jin You
, Jae Hong Kim^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

18 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

Original language	English
Pages (from-to)	373-377
Number of pages	5
Journal	BMB reports
Volume	51
Issue number	8
DOIs	https://doi.org/10.5483/BMBREP.2018.51.8.127
Publication status	Published - 2018

Bibliographical note

Funding Information:
This research was supported by Bio & Medical Technology Development Program Grants (2017M3A9D8063317) and a Mid-Career Researcher Program grant (2017R1A2B4002203) provided by the National Research (NRF) funded by the Ministry of Science, Information and Communication Technologies (ICT), and Future Planning, Republic of Korea. Additionally, this research was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A101032), National Research Foundation of Korea Grant funded by the Korea Government (MSIP, South Korea) (No.2015R1A2A2A01003829) and was also supported by a Korea University grant and the BK21 Plus Program (School of Life Sciences and Biotechnology, Korea University).

Publisher Copyright:
© 2018 by the The Korean Society for Biochemistry and Molecular Biology.

Keywords

BLT2
Leukotriene B4 receptor-2
TNBC
Triple-negative breast cancer

ASJC Scopus subject areas

Biochemistry
Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5483/BMBREP.2018.51.8.127

Cite this

@article{d2c6f407f3da45f1a599eccd5cff85fb,

title = "BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer",

abstract = "Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.",

keywords = "BLT2, Leukotriene B4 receptor-2, TNBC, Triple-negative breast cancer",

author = "Park, \{Jae In\} and Jang, \{Jae Hyun\} and Park, \{Geun Soo\} and Yunro Chung and You, \{Hye Jin\} and Kim, \{Jae Hong\}",

note = "Funding Information: This research was supported by Bio \& Medical Technology Development Program Grants (2017M3A9D8063317) and a Mid-Career Researcher Program grant (2017R1A2B4002203) provided by the National Research (NRF) funded by the Ministry of Science, Information and Communication Technologies (ICT), and Future Planning, Republic of Korea. Additionally, this research was supported by a grant from the Korea Healthcare Technology R\&D Project, Ministry of Health \& Welfare, Republic of Korea (A101032), National Research Foundation of Korea Grant funded by the Korea Government (MSIP, South Korea) (No.2015R1A2A2A01003829) and was also supported by a Korea University grant and the BK21 Plus Program (School of Life Sciences and Biotechnology, Korea University). Publisher Copyright: {\textcopyright} 2018 by the The Korean Society for Biochemistry and Molecular Biology.",

year = "2018",

doi = "10.5483/BMBREP.2018.51.8.127",

language = "English",

volume = "51",

pages = "373--377",

journal = "BMB reports",

issn = "1976-6696",

publisher = "The Biochemical Society of the Republic of Korea",

number = "8",

}

TY - JOUR

T1 - BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

AU - Park, Jae In

AU - Jang, Jae Hyun

AU - Park, Geun Soo

AU - Chung, Yunro

AU - You, Hye Jin

AU - Kim, Jae Hong

N1 - Funding Information: This research was supported by Bio & Medical Technology Development Program Grants (2017M3A9D8063317) and a Mid-Career Researcher Program grant (2017R1A2B4002203) provided by the National Research (NRF) funded by the Ministry of Science, Information and Communication Technologies (ICT), and Future Planning, Republic of Korea. Additionally, this research was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A101032), National Research Foundation of Korea Grant funded by the Korea Government (MSIP, South Korea) (No.2015R1A2A2A01003829) and was also supported by a Korea University grant and the BK21 Plus Program (School of Life Sciences and Biotechnology, Korea University). Publisher Copyright: © 2018 by the The Korean Society for Biochemistry and Molecular Biology.

PY - 2018

Y1 - 2018

N2 - Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

AB - Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

KW - BLT2

KW - Leukotriene B4 receptor-2

KW - TNBC

KW - Triple-negative breast cancer

UR - https://www.scopus.com/pages/publications/85055070963

U2 - 10.5483/BMBREP.2018.51.8.127

DO - 10.5483/BMBREP.2018.51.8.127

M3 - Review article

C2 - 29898809

AN - SCOPUS:85055070963

SN - 1976-6696

VL - 51

SP - 373

EP - 377

JO - BMB reports

JF - BMB reports

IS - 8

ER -

BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this